Left Ventricular Global Longitudinal Strain Is Associated With Cardiovascular Outcomes in Patients Who Underwent

Dae-Young Kim1, Purevjargal Lkhagvasuren1, Jiwon Seo1

  • 1Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Insights

Permanent pacemaker implantation can worsen left ventricular (LV) mechanical function. Impaired LV global longitudinal strain (LV-GLS) after pacing is linked to adverse cardiovascular outcomes in patients.

Area of Science:

  • Cardiology
  • Echocardiography
  • Cardiac Electrophysiology

Background:

  • Permanent pacemaker (PM) implantation poses a risk for left ventricular (LV) systolic dysfunction.
  • Standard LV ejection fraction (LVEF) assessment has limitations in detecting subclinical dysfunction and predicting cardiovascular (CV) outcomes post-PM.

Purpose of the Study:

  • To evaluate the role of LV global longitudinal strain (LV-GLS) in assessing LV mechanical function after PM implantation.
  • To determine if LV-GLS can predict adverse CV outcomes in patients with pacemakers.

Main Methods:

  • Retrospective analysis of 300 patients undergoing PM implantation, excluding those with pre-existing LV dysfunction or other cardiac conditions.
  • LV mechanical function assessed using 2D speckle-tracking echocardiography to measure LV-GLS.
  • CV outcomes defined as a composite of CV death and heart failure hospitalization.

Main Results:

  • Reduced baseline |LV-GLS| and worsening LV mechanical function post-PM were observed in patients with CV outcomes.
  • A post-PM |LV-GLS| cut-off value of 11.2% demonstrated superior predictive ability for CV outcomes (AUC 0.784).
  • Impaired LV-GLS (<11.2%) was independently associated with significantly worse CV outcomes.

Conclusions:

  • Pacemaker use can negatively impact LV mechanical function.
  • LV-GLS is a valuable biomarker for predicting adverse CV outcomes in patients following PM implantation.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
99
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
49
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
71